FOLH1 and prostate cancer: A9 and A10 aptamers are PSMA aptamers screened by Lupold et al. Farokhzad et al. published the first report of targeted drug delivery with nanoparticle-aptamer bioconjugates.243 They used PSMA’s RNA aptamer A10 and polymer nanoparticles to form bioconjugates, and proved that these bioconjugates can effectively target prostate cancer epithelial cells and be more absorbed.